Bispecific Antibodies in Hematologic Malignancies in the Outpatient and Community Settings
Gonugunta, Amrit S Haider, Asad Mohlere, Virginia Aljurf, Mahmoud Hashmi, Shahrukh Abid, Muhammad Bilal
Gonugunta, Amrit S
Haider, Asad
Mohlere, Virginia
Aljurf, Mahmoud
Hashmi, Shahrukh
Abid, Muhammad Bilal
Supervisor
Department
Computer Vision
Embargo End Date
Type
Journal article
Date
License
http://creativecommons.org/licenses/by/4.0/
Language
English
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Bispecific antibodies (BsAbs) are novel antitumor agents that simultaneously engage tumor-associated antigens with CD3 on endogenous effector T cells, leading to cancer cell death. The immune-mediated toxicity rates associated with BsAbs are considerably lower than those seen with CAR T-cell therapy. Hence, widespread utilization of BsAb products in outpatient and community settings will allow greater and more homogeneous access and thus improve patient outcomes. In this review, we discuss the unique toxicities associated with BsAbs currently approved by the U.S. Food and Drug Administration and provide a disease-agnostic framework for the safe community administration of BsAb therapy. With academic, community, and industrial partnerships, broader deployment of BsAbs could be streamlined. Education, provision of in-services, leveraging protocols and experiences, and development of templates and guidelines will make this transition smoother and allow every patient in need of BsAbs to receive timely access to these survival-prolonging therapies.
Citation
A.S. Gonugunta, A. Haider, V. Mohlere, M. Aljurf, S. Hashmi, M.B. Abid, "Bispecific Antibodies in Hematologic Malignancies in the Outpatient and Community Settings," Advances in Hematology, vol. 2026, no. 1, pp. 4529571-4529571, 2026, https://doi.org/10.1155/ah/4529571.
Source
Advances in Hematology
Conference
Keywords
32 Biomedical and Clinical Sciences, 3204 Immunology, 3211 Oncology and Carcinogenesis
Subjects
Source
Publisher
Wiley